BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 18842514)

  • 1. [Effective PAD (bortezomib, doxorubicin, dexamethasone) treatment of a patient with plasma cell leukaemia that has developed after autologous stem cell transplantation].
    Telek B; Méhes L; Batár P; Kiss A; Udvardy M
    Orv Hetil; 2008 Oct; 149(41):1957-9. PubMed ID: 18842514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia.
    Kim SJ; Kim J; Cho Y; Seo BK; Kim BS
    Jpn J Clin Oncol; 2007 May; 37(5):382-4. PubMed ID: 17538191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of secondary plasma cell leukemia resistant to novel agents, in which stringent complete remission was achieved and maintained for a long period of time after VAD therapy and tandem autologous transplantation.
    Sekiguchi Y; Shimada A; Wakabayashi M; Sugimoto K; Tomita S; Izumi H; Nakamura N; Sawada T; Ohta Y; Komatsu N; Noguchi M
    Int J Clin Exp Pathol; 2014; 7(9):6313-22. PubMed ID: 25337285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
    Palumbo A; Gay F; Falco P; Crippa C; Montefusco V; Patriarca F; Rossini F; Caltagirone S; Benevolo G; Pescosta N; Guglielmelli T; Bringhen S; Offidani M; Giuliani N; Petrucci MT; Musto P; Liberati AM; Rossi G; Corradini P; Boccadoro M
    J Clin Oncol; 2010 Feb; 28(5):800-7. PubMed ID: 20048187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
    Sonneveld P; Goldschmidt H; Rosiñol L; Bladé J; Lahuerta JJ; Cavo M; Tacchetti P; Zamagni E; Attal M; Lokhorst HM; Desai A; Cakana A; Liu K; van de Velde H; Esseltine DL; Moreau P
    J Clin Oncol; 2013 Sep; 31(26):3279-87. PubMed ID: 23897961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib in multiple myeloma: treatment and retreatment. A single center experience.
    Warzocha K; Kraj M; Pogłód R; Kwaśniak B
    Acta Pol Pharm; 2008; 65(6):753-6. PubMed ID: 19172860
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two cycles of the PS-341/bortezomib, adriamycin, and dexamethasone combination followed by autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients.
    Lee JH; Lee JH; Kim DY; Kim SD; Choi Y; Kang YA; Seol M; Lee KH
    Eur J Haematol; 2012 Jun; 88(6):478-84. PubMed ID: 22364526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up.
    Popat R; Oakervee HE; Hallam S; Curry N; Odeh L; Foot N; Esseltine DL; Drake M; Morris C; Cavenagh JD
    Br J Haematol; 2008 May; 141(4):512-6. PubMed ID: 18371113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete remission following treatment with bortezomib, doxorubicin, dexamethasone and autologous stem cell transplant in patient with immunoglobulin E multiple myeloma.
    Pogłód R; Kraj M; Kruk B; Hagedorna-Tronina R; Łetowska M; Warzocha K
    Leuk Lymphoma; 2010 Dec; 51(12):2291-4. PubMed ID: 20929320
    [No Abstract]   [Full Text] [Related]  

  • 13. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
    Sonneveld P; Schmidt-Wolf IG; van der Holt B; El Jarari L; Bertsch U; Salwender H; Zweegman S; Vellenga E; Broyl A; Blau IW; Weisel KC; Wittebol S; Bos GM; Stevens-Kroef M; Scheid C; Pfreundschuh M; Hose D; Jauch A; van der Velde H; Raymakers R; Schaafsma MR; Kersten MJ; van Marwijk-Kooy M; Duehrsen U; Lindemann W; Wijermans PW; Lokhorst HM; Goldschmidt HM
    J Clin Oncol; 2012 Aug; 30(24):2946-55. PubMed ID: 22802322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.
    Harousseau JL; Attal M; Avet-Loiseau H; Marit G; Caillot D; Mohty M; Lenain P; Hulin C; Facon T; Casassus P; Michallet M; Maisonneuve H; Benboubker L; Maloisel F; Petillon MO; Webb I; Mathiot C; Moreau P
    J Clin Oncol; 2010 Oct; 28(30):4621-9. PubMed ID: 20823406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma.
    Oakervee HE; Popat R; Curry N; Smith P; Morris C; Drake M; Agrawal S; Stec J; Schenkein D; Esseltine DL; Cavenagh JD
    Br J Haematol; 2005 Jun; 129(6):755-62. PubMed ID: 15953001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia.
    Ataergin S; Arpaci F; Kaya A; Cetin T; Gunhan O
    Am J Hematol; 2006 Dec; 81(12):987-8. PubMed ID: 16888783
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.
    Badros A; Goloubeva O; Fenton R; Rapoport AP; Akpek G; Harris C; Ruehle K; Westphal S; Meisenberg B
    Clin Lymphoma Myeloma; 2006 Nov; 7(3):210-6. PubMed ID: 17229337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Partial recovery of kidney function for an autologous transplant in a patient with chronic kidney disease and multiple myeloma].
    de Alarcón Jiménez RM; Roca Meroño S; Alvarez Fernández GM; García Hernández MA; Navarro Parreño MJ; Jimeno Griñó C; Zarco Pedrinaci E; Molina Núñez M
    Nefrologia; 2011; 31(2):238-40. PubMed ID: 21461027
    [No Abstract]   [Full Text] [Related]  

  • 19. DKK1 correlates with response and predicts rapid relapse after autologous stem cell transplantation in multiple myeloma.
    Lemaire O; Attal M; Bourin P; Laroche M
    Eur J Haematol; 2010 Mar; 84(3):276-7. PubMed ID: 19891699
    [No Abstract]   [Full Text] [Related]  

  • 20. Stringent complete remission of primary plasma cell leukemia with reduced-dose bortezomib, lenalidomide and dexamethasone: a case report and review of the literature.
    Ueda S; Kubo M; Matsuura N; Matsunaga H; Kataoka S; Maeda T; Inui Y; Kawata S; Kanakura Y
    Intern Med; 2013; 52(11):1235-8. PubMed ID: 23728562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.